(Total Views: 514)
Posted On: 03/27/2020 8:11:17 AM
Post# of 145873
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension.
Is that the clue to the label extension? What is a registration-directed study? Rolling in patients from the previous study, so its shortening the trial dramatically? Someone explain that please to me.
This is a great day, all the best to our patients!
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)